AI gets $20M infusion to go on the offensive against Alzheimer’s

The NIH’s National Institute on Aging has awarded $20 million to a new center focused on using emerging technologies—principally AI—to advance understanding of Alzheimer’s disease.

Jointly led by the University of Massachusetts Amherst and Brigham and Women’s Hospital, the center will reside in Amherst and gather experts from elsewhere in the Bay State.

Collaborating institutions are to include Massachusetts General Hospital, Brandeis University and Northeastern University, according to an announcement posted by UMass Amherst Nov. 1.

The center’s co-leaders are computer scientist Deepak Ganesan, PhD, of UMass and Niteesh Choudhry, MD, PhD, an internist at the Brigham and a professor at Harvard Medical School.

The founders are calling the resource the Massachusetts AI and Technology Center for Connected Care in Aging and Alzheimer’s Disease—MassAITC, for short—and saying it will prioritize addressing healthcare disparities associated with Alzheimer’s.

“Artificial intelligence has the potential to transform important areas of science and medicine, but there is a critical need to bring the power of AI to the patients, caregivers and clinicians who need it most,” says Paul Anderson, MD, PhD, senior vice president of research and education at Brigham and Women’s Hospital.

He says the $20 million NIH grant will “allow experts from across our state to come together to help address this key gap.”

UMass Amherst’s Ganesan says MassAITC will seek to solve the hard problem of developing “AI-enhanced sensing technologies that work for people where they are.”

“How do you get good, useful data?” Ganesen adds. “How do you analyze this data … and then how can you intervene in a timely manner when a problem develops?”

In the announcement, UMass Amherst says the new center will ask such questions not only of researchers but also of patients, caregivers, clinicians, behavioral scientists and other stakeholders.

The resulting insights will guide experts developing or refining wearable and contactless sensors, artificial intelligence and machine learning, UMass says.

Full announcement here, MassAITC website here.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.